Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.

2.

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

3.

Woman Loses 6-Year Battle With Mouth Tumor

4.

Shorter but More Intense RT: A Better Option for HNSCC?

5.

Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot